RSS Exagen Gets Conditional Approval For New Lupus And RA Biomarker Assays In New York

Currently reading:
 RSS Exagen Gets Conditional Approval For New Lupus And RA Biomarker Assays In New York

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
12,275
Likes
1,923
Credits
33,750©
Cash
0$
Exagen Inc. (XGN), a specialist in autoimmune testing, has announced that it has garnered conditional approval from the New York State Department of Health for its latest biomarker assays targeting systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). These assays are set for a commercial release in January 2025.

The company highlighted that these new biomarkers will be integrated into its AVISE CTD platform. Together, these enhancements are anticipated to significantly augment the clinical utility of AVISE CTD, equipping healthcare providers with the necessary insights to accurately diagnose patients, thereby reducing the diagnostic journey for those with autoimmune disorders.

For the fourth quarter, Exagen Inc. is forecasting a net loss between $3.4 million and $4.4 million, while expecting revenue to be in the range of $13.3 million to $13.8 million.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom